NEWS
ProAlt at Swiss Biotech Day in Basel, Switzerland
September 07th, 2021 The Swiss Biotech Day is one of the leading biotechnology conferences in Europe coming back on stage on September 7, 2021 after the worldwide COVID-19 pandemic and will take place at Basel Congress Center. Today, PROALT will present to investors and pharma companies the recent advances with the therapeutic monoclonal antibody PA-0661 [...]
ProAlt selected to participate in the EIC Corporate Day with Merck
September 6th, 2021 Protein Alternatives (ProAlt) was selected by the European Innovation Council Business Acceleration Services to present to Merck its therapeutic antibody PA-0661 in oncology. ProAlt will be one of the 16 selected companies from 10 different countries that will present innovative projects to Merck on September 30. Merck, the multinational Healthcare, Life Science [...]
Protein Alternatives will participate in the XX Pharma-Biotech Cooperation Meeting organized by Farmaindustria
April 12th, 2021 The XX Pharma-Biotech Cooperation Meeting will be a digital event organized by FarmaIndustria in April 28, 2021 where selected projects from the Spanish National Research Council (CSIC) and its spin-offs will be presented to pharmaceutical companies. PROALT was selected to present its most advanced therapeutic product PA-0661, a monoclonal antibody for the [...]
Protein Alternatives receives the Innovative SME Seal
April 9th, 2021. PROALT has received the Innovative SME Seal, valid until April 2024. Innovation is one of the key factors for the economic and social development of any country. Through the Innovative SME Seal, the Ministry of Science and Innovation recognizes companies that carry out activities in the field of research, technological development and [...]
ProAlt’s MetasCure project selected in the R&D and innovation programme of Madrid Region
January 14th, 2021 Tres Cantos, Madrid, Spain. Protein Alternatives (PROALT), a leading company in the development of therapeutic monoclonal antibodies in oncology, has been selected as one of the two companies that will receive funding from the R&D and innovation programme of Madrid Region during 2021 and 2022. MetastCure project, with title “Preclinical evaluation of [...]
